NCT04731831 Characterization of Immunogenicity of TNF Inhibitors in Arthritis Patients With Poorer Treatment Response.
| NCT ID | NCT04731831 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Aalborg University Hospital |
| Condition | Arthritis, Rheumatoid |
| Study Type | OBSERVATIONAL |
| Enrollment | 120 participants |
| Start Date | 2020-08-01 |
| Primary Completion | 2025-12-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 120 participants in total. It began in 2020-08-01 with a primary completion date of 2025-12-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of the study is to explore whether the influence of gender, tobacco smoking and obesity on treatment response in tumor necrosis factor inhibitors (TNFIs) can be explained by high degree of inflammation, human leucocyte antigen (HLA) type, autoantibodies, TNF and TNFI concentration and presence of ADA.
Eligibility Criteria
Inclusion Criteria: * Patients \> 18 years * Diagnosed with RA, PsA or AS. * Starting treatment with infliximab or adalimumab. * Co- treatment with csDMARD or glucocorticoid is acceptable. * No new bDMARD is initiated at the time of sampling. Exclusion Criteria: \-
Contact & Investigator
Lene Dreyer, MD, Prof.
PRINCIPAL INVESTIGATOR
Department of Clinical Medicine, Aalborg University and Aalborg University Hospital
Frequently Asked Questions
Who can join the NCT04731831 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Arthritis, Rheumatoid. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04731831 currently recruiting?
Yes, NCT04731831 is actively recruiting participants. Contact the research team at kabula@rn.dk for enrollment information.
Where is the NCT04731831 trial being conducted?
This trial is being conducted at Aalborg, Denmark.
Who is sponsoring the NCT04731831 clinical trial?
NCT04731831 is sponsored by Aalborg University Hospital. The principal investigator is Lene Dreyer, MD, Prof. at Department of Clinical Medicine, Aalborg University and Aalborg University Hospital. The trial plans to enroll 120 participants.